SanaiDr. Nader Sanai, an Associate Professor of Neurological Surgery at the Barrow Neurological Institute in Phoenix, Arizona, has received a $15,000 grant to fund his latest research project, “A Phase 0/II Study of LEE011 in Recurrent Atypical and Malignant Meningioma Patients.”

This proposal represents the first Phase 0 atypical and malignant meningioma trial in history. Dr. Sanai and his team will determine the plasma exposure and brain accumulation of LEE011 following 5-day dosing in patients with recurrent atypical and malignant meningiomas; will evaluate select PD biomarkers corresponding to CDK4/6 inhibition, including Rb phosphorylation, cells in M-phase of cell cycle (PH3), and FoxM1 downregulation and explore the safety and efficacy of LEE011 in recurrent atypical and malignant meningioma with demonstrated pharmacokinetic and pharmacodynamic effects.

Dr. Sanai shares, “What drives me forward is the opportunity to discover things that others in humankind have never seen, as we as find those elusive strategies that can convert terminal diseases like a glioma or malignant  meningioma into more manageable conditions. Having treated so many patients with terminal illness, I remind myself how fleeting life can be and I always try to be as efficient  as possible at work so I can get home and spend time with my family.”

Dr. Sanai is in the process of building a Brain Tumor Center in addition to performing over 300 brain surgeries a year while also overseeing a rising group of young scientists and investigators who are dedicated to brain tumor research.

Meningioma Mommas is proud to partner with Dr. Sanai and his BNI team.